PARIS:VLA

Valneva Announces Successful Outcome of its Annual General Meeting

Valneva appoints new Chair with vaccine-expertise to steer strategy

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Valneva announced at its AGM in Lyon that shareholders approved the 2025 financials, renewed capital authorizations, and relocated its registered office to Lyon. Dr. Gerd Zettlmeissl was named Chair, with Lingelbach remaining CEO and five directors reappointed. The governance refresh could bolster execution on Valneva&#039;s vaccine pipeline, including the Pfizer-partnered Lyme disease program.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Valneva AGM approved all board resolutions; Dr. Gerd Zettlmeissl appointed Chair.</li><li>Zettlmeissl appointment signals governance focus and vaccine-expertise depth.</li><li>Nantes site closure moved registered office to Lyon.</li><li>CEO Lingelbach reappointed; five directors reappointed for varying terms.</li><li>Valneva highlights Pfizer Lyme vaccine collaboration and pipeline opportunities.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Valneva SE (VLA)</strong>: Board chair appointment and AGM outcomes may influence strategic direction and capital allocation.</li><li><strong>Pfizer Inc (PFE)</strong>: Lyme disease vaccine collaboration remains a key pipeline catalyst; milestones to watch.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. Leadership change and structural moves fit governance initiatives; potential to influence execution and investor sentiment over the next 6–12 months.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Chair appointment may boost governance confidence and strategic execution.</li><li>HQ move to Lyon could affect operating costs and tax posture.</li><li>CEO Lingelbach term extension supports pipeline development continuity.</li><li>Pfizer Lyme vaccine collaboration remains a key near-term catalyst; watch updates.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>AGM date: June 25, 2026; resolutions approved.</li><li>2025 financial statements approved; share capital authorizations renewed.</li><li>Registered office moved to Lyon; Nantes site closed.</li><li>Board reappointed: Graffin, Sulat, Jansen (1 year); Connelly (2 years); Lingelbach (3 years).</li><li>Dr. Gerd Zettlmeissl appointed Chair; Graffin remains Vice-chair.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Longer-term upside if governance improves execution; monitor Lyme-Pfizer progress and pipeline milestones.</p>
  </section>
</section>


<article>
  <p><strong>Valneva SE (NASDAQ: VALN, PARIS: VLA)</strong>, a specialty vaccine company, today announced that shareholders approved all resolutions recommended by the Board of Directors at the Company’s Annual General Meeting (AGM), held earlier today in Lyon, France. The AGM confirms governance steps and leadership actions as Valneva advances its vaccine programs and strategic initiatives for long-term value creation for shareholders.</p>

  <section>
    <h2>AGM Highlights: Financials, Share Capital, and Corporate Office</h2>
    <p>Key resolutions adopted at the AGM included the <strong>approval of the 2025 financial statements</strong>, the <strong>renewal of authorizations granted to the Board of Directors</strong> regarding the Company’s <strong>share capital</strong>, and the <strong>transfer of Valneva’s registered office to Lyon</strong> following the closure of its Nantes site.</p>
    <p>Shareholders also approved the reappointment of five Board members. <strong Anne-Marie Graffin</strong>, <strong James Sulat</strong> and <strong Kathrin Jansen</strong> were reappointed for one-year terms, <strong James Connelly</strong> for a two-year term, and Valneva’s <strong>Chief Executive Officer Thomas Lingelbach</strong> for a three-year term.</p>
  </section>

  <section>
    <h3>Leadership Change: Appointment of a New Board Chair</h3>
    <p>At a Board meeting held following the AGM, <strong>Dr. Gerd Zettlmeissl</strong>, an independent director, was appointed as <strong>Chair of the Board of Directors</strong>. Dr. Zettlmeissl is a vaccine expert and biotech entrepreneur with more than 40 years of scientific and leadership experience in the biopharmaceutical industry. During the last 15 years he served as chair of the Board of Directors of several non-profit vaccine organizations as well as public and private biotech companies. He succeeds <strong>Anne-Marie Graffin</strong>, who chaired the Board for the past three years and who will continue as <em>Vice-chair of the Board</em>.</p>
  </section>

  <section>
    <h3>Executive Commentary</h3>
    <p><strong>Gerd Zettlmeissl, chair of Valneva´s Board of Directors, </strong>commented, "I am honored to be appointed chair of the Board and would like to thank Anne-Marie for her outstanding leadership during her tenure. I look forward to working closely with my fellow board colleagues and the management team to support Valneva’s strategic priorities and long-term value creation for shareholders."</p>
  </section>

  <section>
    <h3>Voting Details & Next Steps</h3>
    <p>Detailed voting results will be made available in the "<em>Investors & Media</em>" section of Valneva’s corporate website in the coming days.</p>
  </section>

  <section>
    <h2>About Valneva SE</h2>
    <p><strong>About Valneva SE</strong><br/>We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.<br/>We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines.<br/>Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats. More information is available at <a href="https://www.valneva.com" target="_blank" rel="nofollow">www.valneva.com</a>.</p>
  </section>

  <section>
    <h3>Investor Relations Contacts</h3>
    <ul>
      <li><strong>Valneva Media and Investor Relations Contacts</strong><br/>Laetitia Bachelot-Fontaine<br/>VP Global Communications & European Investor Relations<br/>M +33 (0)6 4516 7099<br/>laetitia.bachelot-fontaine@valneva.com</li>
      <li>Joshua Drumm, Ph.D.<br/>VP Global Investor Relations<br/>M +001 917 815 4520<br/>joshua.drumm@valneva.com</li>
    </ul>
  </section>

  <section>
    <h3>Forward-Looking Statements</h3>
    <p>This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to use and regulatory review of existing products. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties and delays involved in the development and manufacture of vaccines, unexpected clinical trial results or new adverse events, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Valneva is providing this information as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.</p>
  </section>

  <section>
    <h3>Attachment</h3>
    <ul>
      <li><a href="https://ml-eu.globenewswire.com/Resource/Download/b7f38bba-f93a-4205-94e4-42218e5e404b" target="_blank" rel="noopener">2026_06_25_VLA_Post_AGM_PR_EN</a></li>
    </ul>
  </section>

  <img alt="" src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTIwOTYzMSM0MDI0MzQ0OTIjMTAxMTUxMA==" />
  <img alt="" src="https://ml-eu.globenewswire.com/media/ZTI1MGQ4MTMtMDhmNS00NWYyLTkzMmMtZDIzMjAxYjE5NGY3LTEwMTE1MTAtMjAyNi0wNi0yNS1lbg==/tiny/VALNEVA-SE.png" referrerpolicy="no-referrer-when-downgrade" />
  <p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/04f398df-96ac-4b7a-8544-2a2ce2495778"><img src="https://ml-eu.globenewswire.com/media/04f398df-96ac-4b7a-8544-2a2ce2495778/small/val-logo-4c-jpg.jpg" border="0" width="150" height="22" alt="Primary Logo" /></a></p>
</article>

Valneva announced at its AGM in Lyon that shareholders approved the 2025 financials, renewed capital authorizations, and relocated its registered office to Lyon. Dr. Gerd Zettlmeissl was named Chair, with Lingelbach remaining CEO and five directors reappointed. The governance refresh could bolster execution on Valneva's vaccine pipeline, including the Pfizer-partnered Lyme disease program.

Valneva Announces Successful Outcome of its Annual General Meeting

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News